Background: The efforts to treat localized scleroderma, including therapies with potentially hazardous side effects, are often unsatisfactory. Recently, PUVA-bath photochemotherapy has been proven highly effective in the treatment of localized scleroderma. Another form of topical PUVA therapy, 8-methoxypsoralen (8-MOP) containing cream or gel preparations, has been proven to be as effective as PUVA-bath therapy for palmoplantar dermatoses.
Objective: We sought to assess the efficacy of PUVA-cream photochemotherapy in patients with localized scleroderma.
Methods: Four patients with localized scleroderma were included in the study. Diagnosis was confirmed by 20 MHz ultrasound assessment as well as pretreatment skin biopsy specimens from lesional skin. PUVA-cream therapy was performed 4 times a week; all patients received 30 treatments.
Results: PUVA-cream photochemotherapy induced significant clinical improvement or clearance of localized scleroderma in all patients. Clearance was documented by clinical features as well as by 20 MHz ultrasound and histopathologic analysis.
Conclusion: PUVA-cream phototherapy can be highly effective in patients with localized scleroderma even if previous therapy was unsuccessful.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1067/mjd.2000.105503 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ORAL MANIFESTATIONS IN JUVENILE SCLERODERMA: CLINICAL PRESENTATIONS AND HISTOPATHOLOGICAL CHARACTERISTICS.
Georgian Med News
November 2024
Juvenile scleroderma (JS) is a rare chronic connective tissue disorder characterized by stiffening of the skin and soft tissues, including the oral cavity and perioral tissues, leading to fibrosis and a large spectrum of internal organs involvement, cosmetic defects, and early infant disability. The aim of this study was to investigate the histomorphological features of lesions of oral mucosa tissues in children with juvenile scleroderma (JS). 39 JS patients (9 with juvenile systemic sclerosis - JSS and 20 with juvenile scleroderma of head-JSH aged from 5 to 17 years were observed with dental examination and morphological investigation of the dental mucosa.
View Article and Find Full Text PDFExtensive Morphea Following Adjuvant Radiotherapy for Breast Carcinoma-Case Report.
Curr Oncol
January 2025
Dermatology Service, Department of Medicine, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Radiation-induced morphea (RIM) is a rare complication following radiotherapy (RT) for breast cancer treatment. Its distribution is usually confined to the breast having received radiotherapy. A generalized form of RIM also exists, defined as lesions extending beyond the radiotherapy site, but data on the subject are scarce in the literature.
View Article and Find Full Text PDFA case of localized scleroderma with variable response to excimer light therapy.
J Dermatol
January 2025
Division of Dermatology, Department of Internal Related, Kobe University, Kobe City, Hyogo, Japan.
Comparative study between fractional CO laser (10,600 nm) and microneedling in treatment of morphea: dermoscopic and histopathological evaluation.
Arch Dermatol Res
January 2025
Dermatology and Venereology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Morphea is a chronic inflammatory fibrosing disorder. Since fibrosis is the hallmark of both scars and morphea, our attention was raised for the possible use of Fractional Ablative CO lasers and microneedling as treatment modalities for morphea. To compare the efficacy and safety of Fractional Ablative CO lasers and microneedling in the treatment of morphea.
View Article and Find Full Text PDFErlotinib-induced Perioral Lesions Resembling Scleroderma.
Acta Dermatovenerol Croat
November 2024
Constantin A. Dasanu MD, PhD, Lucy Curci Cancer Center, Eisenhower Health, 39000 Bob Hope Dr, Rancho Mirage, CA 92270 , USA;
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is currently used in the therapy of several solid malignancies. This agent has been associated with several dermatological side-effects, the most common being papulo-pustular acneiform rash. Herein we describe a unique skin effect in a patient treated with erlotinib for non-small cell lung cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!